Melanoma-associated antigen-HLA class II complex (MAA-HLA-II complex)

Melanoma-associated antigens (MAAs) presented in HLA class II complexes are a specialized class of therapeutic targets that facilitate the recognition of tumor cells by CD4+ helper T cells. While traditional immunotherapy has focused on HLA class I-restricted antigens for CD8+ T cell activation, the presentation of antigens such as MAGE-A3, NY-ESO-1, and tyrosinase on HLA-DR, HLA-DP, or HLA-DQ molecules is essential for a sustained and robust anti-tumor response (PubMed: 15155838). These complexes are formed when tumor proteins are processed endogenously or exogenously and loaded onto MHC class II molecules, which are often upregulated in the melanoma microenvironment or expressed directly by the melanoma cells (PubMed: 25108520). Therapeutic targeting of these complexes primarily involves the use of cancer vaccines and T-cell receptor (TCR) engineered T-cell therapies. For instance, TCR-T therapies targeting MAGE-A3 in the context of HLA-DPB1*04:01 have been evaluated in clinical trials to leverage the potent helper and cytotoxic functions of CD4+ T cells (NIH: NCT02111850). The clinical success of these therapies depends on the precise matching of the patient's HLA haplotype with the specific peptide epitope and the high-level expression of the target antigen within the tumor. However, challenges remain, including the risk of off-target cross-reactivity with healthy tissues and the potential for tumors to escape immune detection by downregulating HLA class II expression (Nature Reviews Cancer: 10.1038/nrc.2016.25).

Other names

Tumor-associated antigen-HLA class II complexMAGE-HLA class II complexNY-ESO-1-HLA class II complexCancer-testis antigen-HLA class II complexpMHC II complexMHC class II-restricted melanoma antigen

Activation of antigen-specific CD4+ T lymphocytes through T-cell receptor (TCR) recognition of the specific peptide-HLA class II complex, leading to the secretion of pro-inflammatory cytokines (e.g., IFN-gamma, TNF-alpha) and the orchestration of a broader anti-tumor immune response, including the recruitment and support of CD8+ cytotoxic T cells (PubMed: 25108520, 15155838).